Advertisement
U.S. Markets closed

InnoCan Pharma Corporation (INNPF)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
0.10550.0000 (0.00%)
At close: 04:00PM EDT
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,440
-
2,559
196
8
0
Cost of Revenue
919
-
452
75
5
0
Gross Profit
521
-
2,107
121
3
0
Operating Expense
7,651
-
8,373
7,601
4,728
3,001
Operating Income
-7,130
-
-6,266
-7,480
-4,725
-3,001
Net Non Operating Interest Income Expense
0
-
19
-13
-8
-334
Other Income Expense
3,806
-
2,359
-2,598
-5,220
-
Pretax Income
-3,324
-
-3,888
-10,091
-9,953
-3,335
Tax Provision
0
-
1
0
0
0
Net Income Common Stockholders
-3,129
-
-3,764
-10,047
-9,953
-3,335
Diluted NI Available to Com Stockholders
-3,129
-
-3,764
-10,047
-9,953
-3,335
Basic EPS
-0.02
-0.02
-0.02
-0.05
-0.06
-
Diluted EPS
-0.02
-0.02
-0.02
-0.05
-0.06
-
Basic Average Shares
252,653
257,004
248,953
224,542
162,022
-
Diluted Average Shares
252,653
257,004
248,953
224,542
162,022
-
Total Operating Income as Reported
-7,130
-
-6,266
-7,480
-4,725
-3,001
Rent Expense Supplemental
-
-
198
84
-
-
Total Expenses
8,570
-
8,825
7,676
4,733
3,001
Net Income from Continuing & Discontinued Operation
-3,129
-
-3,764
-10,047
-9,953
-3,335
Normalized Income
-6,935
-
-5,505
-7,449
-4,733
-3,335
Interest Income
18
-
21
-
-
-
Interest Expense
4
-
2
13
8
334
Net Interest Income
0
-
19
-13
-8
-334
EBIT
-9,728
-
-3,886
-10,078
-9,945
-3,001
EBITDA
-9,693
-
-3,851
-10,035
-9,905
-2,978
Reconciled Cost of Revenue
919
-
452
75
5
0
Reconciled Depreciation
35
-
35
43
40
23
Net Income from Continuing Operation Net Minority Interest
-3,129
-
-3,764
-10,047
-9,953
-3,335
Total Unusual Items Excluding Goodwill
3,806
-
2,359
-2,598
-5,220
-
Total Unusual Items
3,806
-
2,359
-2,598
-5,220
-
Normalized EBITDA
-13,499
-
-6,210
-7,437
-4,685
-2,978
Tax Rate for Calcs
0
-
0
0
0
0
Tax Effect of Unusual Items
0
-
618.2939
0
0
0